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SUMMARY
BACKGROUND AND OBJECTIVES: There are very 
few publications on pain amplification syndrome in the 
elderly (PAS), in spite of its importance for them, be-
cause it may have multiple consequences during aging. 
This study aimed at reporting a case of PAS in the 
elderly represented by fibromyalgia (FM), describing its 
diagnostic approach and therapeutic management, and at 
presenting a literature review on the subject.
CASE REPORT: Female patient, 73 years old, with 
moderate diffuse muscle pain, fleeting morning stiff-
ness, anhedonia, sadness, anxiety, major fatigue and 
sleep disorders for four years. She was initially diag-
nosed as rheumatic polymyalgia and was under regular 
prednisone in spite of the progressive worsening of her 
functional capacity and quality of life (QL). One year 
ago her diagnosis was reviewed by our service and we 
confirmed it was PAS, spectrum of FM. Prednisone was 
then withdrawn and non-pharmacological therapy was 
indicated with pain self-management program; multi-
modal pharmacological therapy was also instituted 
with non-opioid (lysine clonixinate) and opioid (trama-
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dol) analgesics and a pain modulator (duloxetine). Six 
months later there has been major pain, sleep, depres-
sion, anxiety, functional capacity and QL improvement. 
CONCLUSION: Accurate diagnosis and adequate 
therapeutic intervention are paramount for PAS cases, 
especially in the elderly population with FM, which 
has unique characteristics in such population. There 
are major probabilities of symptomatic, functional 
and QL improvement in the elderly with PAS if we 
pay attention to differential diagnoses and introduce 
adequate therapies.
Keywords: Differential diagnoses, Elderly, Fibromyal-
gia, Pain amplification syndrome.
RESUMO
JUSTIFICATIVA E OBJETIVOS: Pouquíssimas 
são as publicações sobre a síndrome de amplificação 
dolorosa no idoso (SAD), a despeito da sua importância 
para aqueles indivíduos, pois pode ter múltiplas con-
sequências no envelhecimento. O objetivo deste estudo 
foi relatar um caso de SAD no idoso; representada pela 
fibromialgia (FM), descrevendo sua abordagem diagn-
óstica e seu manuseio terapêutico, bem como apresentar 
uma revisão bibliográfica do assunto.
RELATO DO CASO: Paciente do gênero feminino, 73 
anos, há 4 anos iniciando um quadro de moderada dor 
muscular difusa, rigidez matinal fugaz, anedonia, tristeza, 
ansiedade, importante fadiga e distúrbio do sono. Inicial-
mente, diagnosticada polimialgia reumática, assim, vinha 
fazendo uso regular de prednisona, apesar de progres-
siva piora da sua capacidade funcional e qualidade de 
vida (QV). Há um ano, no nosso serviço, foi revisto o 
diagnóstico, e verificado tratar-se de SAD, espectro 
da FM. Suspendeu-se, então, a prednisona e orientado 
terapia não farmacológica com programa de autogeren-
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ciamento em dor, e farmacológica multimodal com an-
algésicos não opioide o clonixinato de lisina e opioide o 
tramadol, e um modulador da dor, a duloxetina. Após 6 
meses de tratamento verificou-se grande melhora na dor, 
sono, depressão, ansiedade, capacidade funcional e QV. 
CONCLUSÃO: É de suma importância o diagnóstico 
correto e uma intervenção terapêutica adequada nos 
casos de SAD, especialmente tratando-se da população 
idosa e da FM, a qual apresenta características pecu-
liares naquela população. Há grandes probabilidades de 
melhora sintomática, funcional, e na QV dos idosos com 
SAD ao se atentar para aos diagnósticos diferenciais, 
bem como ao se introduzir terapêuticas adequadas. 
Descritores: Diagnósticos diferenciais, Fibromialgia, 
Idoso, Síndrome de amplificação dolorosa.
INTRODUCTION
Population aging is a worldwide phenomenon with un-
precedented levels. Only in Brazil, the elderly popula-
tion shall double in the next two decades and may reach 
30 million of individuals1. This fact is followed by in-
creased frequency of cases related to pain complaints. 
Pain, for its prevalence and impact, is considered today 
a major public health problem. Older people are espe-
cially more susceptible to chronic pain, which ends up 
contributing to functional impairments and also worse 
quality of life scores (QL)2.
Pain amplification syndrome (PAS) has significantly in-
creased in recent years, also including the aging popu-
lation. However, there are still few studies specifically 
addressing it in the elderly.
Fibromyalgia (FM) is a major PAS presentation, which 
is seldom addressed and discussed in aging people, es-
pecially in Brazil.
This study aimed at reporting a PAS case as well as at re-
viewing FM spectrum in the literature, describing diag-
nostic approaches and adopted therapies, in addition to 
presenting a scientific-literary review on the subject.
CASE REPORT
Female patient, 73 years old, artisan, with hyperten-
sion, spinal osteoporosis and osteoarthritis, who re-
ferred paresthesia and sensation of edema on hands, 
moderate diffuse muscle pain, fleeting morning stiff-
ness, anhedonia, sadness, anxiety, major fatigue and 
sleep disorders for four years. She was being followed 
by other health service since the beginning of symp-
toms with diagnosis of polymyalgia rheumatica.
So, since that time she was under regular steroids 
with 10 mg prednisone/day. She referred initial pain 
improvement but her functional capacity was progres-
sively worsening.
She is being followed by our service for one year and was 
initially submitted to evaluation especially addressing the 
different aspects of her pain: moderate intensity by the ver-
bal scale, and equal to 5 by the numerical verbal scale, con-
tinuous, diffuse and heavy chronic pain but with exacerba-
tion periods, interference with her executive functionality 
with partial dependence for complex daily life activities, 
interference with her affection with depression and anxiety 
followed by fatigue and sleep disorders.
Physical evaluation has shown just hyperalgesia in upper 
and lower limbs. We suspected of PAS, FM spectrum, 
and requested several laboratory tests, including inflam-
matory tests, vitamin D, CPK, thyroid, parathyroid, 
kidney and liver function, among others, and all were 
within reference values, except for VHS of 40 mm in 
the first hour. Compared to tests of three years ago, VHS 
was 43 mm in the first hour. We have also requested 
shoulders ultrasound, which has not shown significant 
changes. Bone densitometry was not performed because 
she missed her appointments several times.
With the higher possibility of really being FM, we have 
gradually withdrawn prednisone and established a new 
treatment: pain self-management program with guidance 
and exercises, educational measures, physical measures 
at home, such as the use of stupes, coping, cognitive-
behavioral measures and multimodal pharmacological 
therapy with non-steroid analgesic (125 mg lysine clo-
nixinate every 8 hours) and opioid analgesic (50 mg 
tramadol every 8 hours) intercalated by 14 days of du-
loxetine (60 mg/day).
Six month later she returned referring that she was ac-
curately complying with our guidance and that there 
had been major improvement in her general status with 
significant pain, sleep, depression and anxiety improve-
ment with major improvement of her functional cap-
acity and QL.
DISCUSSION
In this case, it was observed that only after three years 
of medical follow-up and prolonged treatment with 
steroids the correct diagnosis was established. Since 
the beginning, a major disproportion between symp-
toms and findings was observed. Pain was not severe 
but interfered a lot with her affection, functionality and 
sleep, and was associated to major fatigue.
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In the “pain puzzle”, PAS is considered a new piece 
that, in turn, belongs to a group of conditions especially 
characterized by pain without associated organic cause, 
or even by symptoms disproportional to findings. So, 
there is chronic pain the intensity of which is not ob-
jectively explained3. Such condition has also been 
called functional pain syndrome.
Traditionally, most patients affected visit many 
physicians, including different specialties ac-
cording to predominant symptoms and in general, 
abnormalities which could fully explain the symp-
toms are not identified.
PAS has a wide presentation spectrum being most fre-
quent the musculoskeletal forms. But in addition to 
PAS musculoskeletal forms, other chronic conditions 
have been observed in recent years, such as chronic fa-
tigue syndrome, headaches, irritable colon and bladder 
syndromes, restless legs syndrome, and periodic limbs 
movement syndrome, among others. They have similar 
conditions with common features based on their bio-
pathophysiological knowledge4,5.
PAS musculoskeletal spectra, for being very frequent, 
will be deeper discussed. They are classified into local-
ized and generalized forms. 
Localized musculoskeletal PAS are especially recog-
nized by the following syndromic diagnoses: complex 
regional pain syndrome type 1, which is less common 
in the elderly; miofascial pain syndrome, more fre-
quent above 60 years of age; and temporomandibular 
dysfunction syndrome5. These forms affect just some 
body regions, being characterized by hyperalgesia and 
allodynia, but also by trophic changes in affected tis-
sues. It is less frequent in hands and feet, very often 
preventing the use of shoes or socks, which ends up 
limiting daily activities6.
These localized forms tend to generalization when they 
are not adequately treated, so accurate diagnoses and 
approaches are relevant. Miofascial pain syndrome is 
highly prevalent in the elderly and is associated to ex-
cessive muscle use thus being also called muscle stress 
syndrome. It is characterized by muscle pain, strained 
muscle bands and trigger-points (TP) located in muscles, 
skin, tendons, periosteum and ligaments very sensitive to 
stimulations, generating local and/or referred pain7. TP 
may be evident with biological aging, causing motor in-
coordination by excitability disorders and motoneurons 
nervous conduction, preventing the synchronization of 
nervous contractions of synergist muscles.
Generalized musculoskeletal PAS are characterized by 
the presence of muscle and joint pain symptoms, the lat-
ter less frequent, which are diffuse in different body re-
gions. These symptoms are followed by neurovegetative 
disorders. Some changes in normally presented charac-
ters are typical of generalized PAS and very often exter-
nal influences may be recognized as causing them8. Most 
people affected report more severe pain during weath-
er changes or when the weather is cold and wet. They 
feel better in warm and dry weather and physical stress 
worsens a lot the disorders8. Major nosological entity of 
this group is FM.
Among risk factors for the onset and maintenance of 
generalized PAS there are age, female gender, family his-
tory of chronic pain, obesity and more deficient mental 
and/or physical status9. Factors negatively influencing 
generalized form results are: high levels of psychological 
disorders, somatization, fatigue, poor sleep, higher num-
ber of painful areas, pain intensity, mental status and im-
paired functional capacity, comorbidities and higher num-
ber of medical visits to primary care institutions9. Mild 
alcohol consumption and individualized social support 
seem to have protective effects9.
As to genesis, PAS has been described as multifactorial. 
It is believed that involved factors are especially genetic, 
environmental such as traumas, infections, emotional 
stress, adverse childhood experiences and patterns learn-
ed to face pain. It seems clear that this is not a primary 
psychiatric condition and that there is no need for psycho-
logical factors for its genesis, because most patients do 
not have active psychiatric diseases or even a specific type 
of personality, such as obsessive-compulsive disorders. 
However, depression is very frequent. It is impossible 
to determine whether psychological factors are primary, 
simultaneous or secondary8.
As to involved pathophysiological mechanisms, there are 
major associations with somatosensory system dysfunc-
tion, with abnormal pain processing by central nervous 
system, with neuroendocrine system dysfunction evi-
dencing changes in the hypothalamic-pituitary-adrenal 
axis and with failure of the stress response system, with 
adaptation deficit to physical or psychical overload8.
Experimental studies have shown the presence of high 
nitric oxide levels in the muscles, in addition to low 
phosphorylation and muscle oxidative capacity poten-
tial, such as decreased muscle phosphocreatine, ATP 
and increased substance P. Such changes could help 
pain sensitization and amplification shown by primary 
afferent nociceptors changes, with increased neuronal 
and receptive neuronal fields excitability, that is, there 
would be an increase in the referred pain area, or afferent 
hypersensitivity.
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There is central sensitization with increased substance P and 
dynorphin in the CSF, increased temporal summation and 
somatosensory potential by skin stimulations, decreased 
nociceptive inhibitory control system activity, with sero-
toninergic dysfunction evidenced by decreased serotonin 
and its precursors levels10. Among neuroendocrine changes 
and abnormal responses to stress there are abnormal ACTH 
and urinary cortisol levels with decreased cortisol response 
and sympathetic nervous system hyperactivity11.
In general, PAS diagnosis is based on clinical findings 
because laboratory and imaging results are normal. Its 
identification depends on a good communication be-
tween patients and physicians, which will allow the ob-
servation of sensory, emotional and cognitive involve-
ment of patients. Sometimes the elderly have communi-
cation limitations, such as visual and auditory deficits12.
Specifically for elderly people, one should always check 
chronic pain impact on functional capacity, that is, im-
pact on physical, mental, social and executive-functional 
dimensions, in addition to QL. PAS represents a major 
impact on their lives13. From the physical and mental 
point of view, chronic pain often contributes to gait dis-
orders with ambulation impairment, thus leading to loss 
of fitness and also to falls.
In terms of executive functionality, chronic pain often 
brings a higher degree of functional dependence for 
instrumental and basic daily life activities. In the social 
dimension, there is increased use of medical services 
and higher family expenses, which frequently helps im-
pairing QL, isolating individuals from important social 
stimulations and amplifying functional and emotional 
losses caused by untreated pain. In general, patients ex-
perience major physical distress, fatigue, depression and 
sleep disorders, in addition to other potentially debilitat-
ing overlapping conditions14.
It is important to understand PAS effects on functional 
independence and QL of the elderly for effective treat-
ment strategies. Moderate chronic pain has negative in-
fluences, so health professionals should be always alert 
and use evaluation methods which may identify the 
magnitude of the pain, since very often the elderly are 
unable to adequately express their pains, thus offering 
all necessary health support15.
Central desensitization is critical for an adequate 
therapy. Antidepressants, anticonvulsants, NMDA re-
ceptor antagonists, psychotherapy and sleep improve-
ment may be very successful. So, pharmacological 
and non-pharmacological approaches are always re-
quired and currently they may be powerful interven-
tions to manage PAS.
Among PAS in the elderly population, FM deserves 
attention since there are few scientific studies ad-
dressing this subject specifically in Geriatrics. It is 
believed that FM in the elderly population is often 
inaccurately diagnosed and as a consequence is 
inadequately treated and this is why further investi-
gations and disclosures on the subject are justified. 
A very important fact is that the elderly experience 
different levels of “fibromyalgia symptoms” as com-
pared to younger people16.
There are many studies on FM prevalence but most 
of them address the population where this disease 
is more frequent – between 30 and 60 years of age17. 
Considering the Brazilian population one more fact 
should be taken into consideration: those prevalence 
studies were carried out in countries with different char-
acteristics from our study.
Most frequent FM cases in the population are found in 
the program The Community Oriented Program for Con-
trol of Rheumatic Disease (COPCORD) created by the 
World Health Organization (WHO) and the International 
League of Associations of Rheumatology (ILAR). How-
ever, the studies involved in this program address major 
age intervals and several rheumatic diseases, thus im-
pairing FM prevalence results, especially in the elderly. 
In addition, among them, just one Brazilian study has 
specifically addressed the elderly population. This latter 
has found FM prevalence of 1.9% in older individuals 
between 55 and 74 years of age18.
An American study with more specificity for FM has 
found prevalence of 5.4% for people above 60 years of 
age19. A French study has found prevalence of 2.8% and 
4.1% for ages between 65 and 74 years and 75 to 84 
years, respectively20.
Little has been discussed in published studies about FM 
characteristics in the elderly, so it is unknown whether 
ethnic, cultural and / or environmental variables would 
differ in addressed elderly populations. In general, there 
is always predominance of the female gender, which in 
turn would consider gender as pain predisposing factor, 
based on biological, hormonal and social factors.
There are currently two diagnostic criteria for FM. Ac-
cording to the American College of Rheumatology 
(ACR), whose criteria are internationally recognized, 
it has to be diffuse pain for three months or more and 
have 11 out of 18 tender points (anatomical areas with 
excessive pain sensitivity at palpation, being typically 
areas of muscles and tendons insertion)21. More recently, 
Wolfe et al criteria22 require the presence of 4 or 5 tender 
points and several overlapping symptoms such as cog-
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nitive changes, fatigue, sleep disorders and depression. 
What has encouraged discussions about these recently 
developed criteria was the determination of the tender 
points, which are very subjective and vary according to 
the examiner and the occasion.
Some patients may identify factors triggering or worsen-
ing their pain, among them virus infection, physical 
and psychical traumas, weather changes, inactivity and 
anxiety. In general, in addition to persistent pain, most 
have fatigue14 in addition to other complaints, among 
them: sleep disorders, tension headache or migraine, 
irritable colon, Raynaud phenomenon, subjective 
edema of soft tissues, concentration difficulty, dry 
mouth and eyes, palpitation, paresthesia in upper and / 
or lower limbs, sensitivity to some foods and medica-
tions, depression and / or history of depression23. Some 
diseases are very similar to FM.
A study comparing 31 individuals with FM onset after 
60 years of age and other 63 individuals where its onset 
was before 60 years of age, has found that in 40% of 
them rheumatoid arthritis or polymyalgia rheumatica 
had been incorrectly diagnosed17. These individuals were 
submitted to oral steroids, which is a problem especially 
for the elderly population. An important observation in 
this same study was the recognition that FM was present 
in just 17% of the elderly with that condition.
With aging, FM symptoms become unique. Younger 
people refer pain as the worst symptom while the elderly 
refer more fatigue, swelling and depression16, being less 
frequent headaches, self-report of anxiety and depres-
sion, symptoms worsening by weather conditions, men-
tal effort or sleep disorders16. The elderly may even be 
less symptomatic than middle-age adults, as shown by a 
recent study24, however the importance of their clinical 
status is still noted.
Peripheral nociceptive reductions are still very use-
ful to treat FM in the elderly, particularly for muscles, 
improvements or preventions of central sensitization and 
the management of associated negative effects, espe-
cially depression. In studies involving pharmacological 
therapy efficacy in the elderly, in addition to efficacy, 
tolerability and comorbidities were also very important. 
Treatments for elderly individuals should be adapted to 
meet their unique needs, taking into account their indi-
vidual health.
The pharmacological treatment includes some classes of 
drugs. Non-steroid anti-inflammatory drugs (NSAIDs) 
seem to have a synergic effect when combined to drugs 
acting on the central nervous system, however one has to 
be more cautious with the elderly.
Antidepressants, among them tricyclic25, amitriptyline 
and nortipritlyne, are the drugs of choice and may im-
prove, pain, sleep, depression, stress and anxiety. How-
ever they should also be carefully used by the elderly 
due to their adverse effects. Double-action inhibitors 
are more on focus, with evidences for duloxetine. In a 
multicenter study also involving the elderly with FM, 
but with mean age of 49 years, duloxetine during 12 
weeks has considerably improved females’ pain inten-
sity, stiffness and QL26.
Antiepileptic drugs, such as gabapentin27, pregabalin28, 
topiramate, carbamazepine and lamogrigine may also 
be used. A recent study using duloxetine and pregabalin 
for 12 months, also involving the elderly but with mean 
age of 50 years, has shown different dose patterns for 
each drug29. In this study, mean daily duloxetine dose 
was relatively more stable along time, while there has 
been significant pregabalin dose increase during the 
period, with mean daily dose of 55.6 mg/person for du-
loxetine and 195.7 mg/person for pregabalin, thus im-
plying higher costs for pregabalin.
Neuromuscular blockers, such as cyclobenzaprine30, 
carisoprodol and tizanidine are also part of the thera-
peutic armamentarium, as well as dopaminergic 
agonists.
As to non-pharmacological therapy, of major 
importance, the key-aspect would be patients’ educa-
tion by explaining the disease. Exercises, in their dif-
ferent modalities, are also mandatory. Strength training, 
especially for elderly patients, is becoming an area of 
major interest due to several functional health benefits31. 
Physical exercises should be carefully oriented other-
wise the may pose risks to the elderly because factors 
such as age, fitness level, exercise intensity and overlap-
ping conditions determine favorable or unfavorable re-
sults12. Cognitive-behavioral therapy, yoga and all types 
of massages may bring symptoms relief32. Acupuncture 
has obtained results for FM, however for a short period.
In summary, to date, FM treatment is symptomatic and 
should be multidisciplinary with the association of phar-
macological and non-pharmacological therapies, high-
lighting multimodal therapies.
Polymyalgia rheumatica in the elderly may really have 
several differentials (Table 1)33, so one should be cau-
tious because a wrong treatment with steroids, which 
are the drugs of choice for polymyalgia rheumatica, may 
bring severe problems, especially for the elderly. Mild 
HSV increases are common in the geriatric population 
and very often have no clinical significance. Currently, 
shoulders ultrasound is being useful to help differential 
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polymyalgia rheumatica diagnosis and usually shows 
bilateral subacromial/subdeltoid bursitis34,35. This lat-
ter has high sensitivity and specificity for polymyalgia 
rheumatica and has been suggested as a new diagnostic 
criterion since it is altered both in cases of high or nor-
mal HSV35.
After a correct diagnosis and guided and carefully fol-
lowed clinical treatment, there has been significant PAS 
improvement. 
Supported by literature review, multimodal pain therapy 
is very effective and is based on the premise that, when-
ever possible, drugs and techniques with synergic phar-
macokinetic and / or pharmacodynamic effects should 
be associated to relieve pain. This would allow a more 
rational use with lower drug doses and less side effects. 
The pain self-management program36 adopted in this 
clinical case was very important for the analgesic treat-
ment and aimed at decreasing pain, improving mood 
and psychosocial functioning of the patient. There has 
been also contribution of the pharmacological therapy 
with prescription of opioid analgesics such as tramadol, 
of non-opioid analgesics such as lysine clonixinate, this 
latter with proved analgesic efficacy and tolerability 
for the elderly37, and prescription of duloxetine, a pain-
modulating drug.
PAS management in the elderly is still a major chal-
lenge. In our case, patient was submitted to a long 
treatment with steroids, which represented at least a 
major problem for her with significant increase of the 
risk of fractures.
It is very important to identify PAS in the elderly 
knowing that in younger people pain is the worst symp-
tom while in the elderly most common symptoms are 
fatigue, swelling and depression11. They have also 
less complaints of chronic headache, self-report of 
anxiety and stress, symptoms worsening by weather 
factors, mental effort or sleep disorders. Due to the 
major distress and functional impairment that PAS 
may bring, health professionals should pay attention 
to the list of possible diagnoses for the elderly with 
diffuse pain. Currently, even other aspects have been 
studied with regard to diffuse pain, such as the speed 
of psychomotor processing which is very important 
during aging. A study has found association between 
generalized chronic pain and slower cognitive process-
ing speed in community elderly people38.
So, PAS should not be overlooked in the elderly. All 
attention should be driven to diagnosis and treatment, 
looking for releasing symptoms which may impair a 
successful aging. There are major probabilities of symp-
Table 1 – Differential fibromyalgia diagnoses
Diagnoses When to consider Suggestions
Hypothyroidism 
Consider almost always, but seldom its treatment 
improves FM symptoms
TSH, free T4
Hyperparathiroidism Bone and kidney manifestations
Serum calcium, PTH
Polymyalgia rheumatica
Pain in scapular and pelvic girdle, morning stiffness 
and arthritis.
HSV, PCR, and shoulders US or 
MRI, also as an option
Polymyositis Muscle weakness CPK, aldolase
Multiple myeloma
Diffuse bone pain, emaciation, renal failure, anemia, 
serum calcium increase
Protein electrophoresis, Bence 
Jones U.
Osteomalácia Bone loss, bone pain, Anserine gait, pseudofractures
Vitamin D, calcium, phosphorus, 
alkaline phosphatase
Sjögren S. Sicca symptoms, fatigue, arthritis Anti-Ro, anti-La
Drug myopathy
Statines, fibrates, H2 blockers, steroids, cocaine, 
canabis
Withdraw the drug
Early Parkinson’s disease Bradykinesia, shivering, stiffness, fatigue Parkinson’s disease management
US = ultrasound; MRI = magnetic resonance imaging; FM = fibromyalgia.
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tomatic, functional and QL improvement of the elderly 
with PAS if we pay attention to their differential diagno-
ses and introduce adequate therapies.
CONCLUSION
PAS in the elderly is still poorly diagnosed in spite of the 
major clinical importance of its repercussion, especially 
in the case of FM spectrum, which has unique features in 
patients. Significant clinical improvement of our clinical 
case implied considering several differential diagnoses 
and guidance for multimodal therapy.
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